IPA logo

ImmunoPrecise Antibodies (IPA) Cash From Financing

Annual CFF

$756.00 K
+$1.22 M+261.88%

April 30, 2024

Summary

Performance

1-Year Change

+261.88%

3-Year Change

-97.72%

5-Year Change

-89.35%

15-Year Change

-68.55%

IPA Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

34.67%
IPA annual cash flow from financing activities is higher than 34.67% of companies in Healthcare sector

High & Low

All-time High

$33.15 M
IPA annual cash flow from financing activities is currently -97.72% below its historical high of $33.15 million

3-Year Low

-$467.00 K

Earnings dates

Last Annual Earnings Report Date

Apr 30, 2024
IPA previous annual earnings announcement was published on Apr 30, 2024

Next Annual Earnings Report Date

N/A
IPA next annual earnings announcement has not yet been scheduled

OtherIPAcash flowmetrics:

Annual CFI

-$1.16 M
IPA annual cash flow from investing activities is -$1.16 million

Annual CFO

-$3.14 M
IPA annual cash flow from operations is -$3.14 million

Annual FCF

-$4.18 M
IPA annual free cash flow is -$4.18 million

Annual CAPEX

$1.03 M
IPA annual capital expenditures is $1.03 million

Quarterly CFF

$1.52 M
-$446.80 K-22.70%

October 31, 2024

Summary

Performance

3-Month Change

-22.7%

1-Year Change

-22.7%

3-Year Change

-22.7%

5-Year Change

-22.7%

IPA Quarterly CFF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

67.25%
IPA quarterly cash flow from financing activities is higher than 67.25% of companies in Healthcare sector

High & Low

All-time High

$21.78 M
IPA quarterly cash flow from financing activities is currently -93.01% below its historical high of $21.78 million

3-Year Low

-$303.30 K

Earnings dates

Last Quarterly Earnings Report Date

Oct 31, 2024
IPA previous earnings announcement was published on Oct 31, 2024

Next Quarterly Earnings Report Date

Mar 14, 2025
IPA next earnings announcement is scheduled for Mar 14, 2025

OtherIPAcash flowmetrics:

Quarterly CFI

-$48.20 K
IPA quarterly cash flow from investing activities is -$48.20 thousand

Quarterly CFO

-$1.65 M
IPA quarterly cash flow from operations is -$1.65 million

Quarterly FCF

-$1.70 M
IPA quarterly free cash flow is -$1.70 million

Quarterly CAPEX

$48.20 K
IPA quarterly capital expenditures is $48.20 thousand

TTM CFF

$4.77 M
+$1.74 M+57.62%

October 31, 2024

Summary

Performance

3-Month Change

+57.62%

1-Year Change

+57.62%

3-Year Change

+57.62%

5-Year Change

+57.62%

IPA TTM CFF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

41.94%
IPA TTM cash flow from financing activities is higher than 41.94% of companies in Healthcare sector

High & Low

All-time High

$33.15 M
IPA TTM cash flow from financing activities is currently -85.60% below its historical high of $33.15 million

3-Year Low

-$1.02 M

Earnings dates

Last Quarterly Earnings Report Date

Oct 31, 2024
IPA previous earnings announcement was published on Oct 31, 2024

Next Quarterly Earnings Report Date

Mar 14, 2025
IPA next earnings announcement is scheduled for Mar 14, 2025

OtherIPAcash flowmetrics:

TTM CFI

-$1.02 M
IPA TTM cash flow from investing activities is -$1.02 million

TTM CFO

-$5.70 M
IPA TTM cash flow from operations is -$5.70 million

TTM FCF

-$6.66 M
IPA TTM free cash flow is -$6.66 million

TTM CAPEX

$954.50 K
IPA TTM capital expenditures is $954.50 thousand

Cash From Financing Formula

CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities

IPA Cash From Financing Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+261.9%-22.7%+57.6%
3 y3 years-97.7%-22.7%+57.6%
5 y5 years-89.3%-22.7%+57.6%

IPA Cash From Financing Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-97.7%+261.9%-37.6%+601.6%-78.0%+565.6%
5 y5-year-97.7%+261.9%-93.0%+601.6%-85.6%+565.6%
alltimeall time-97.7%+261.9%-93.0%+451.7%-85.6%+565.6%

ImmunoPrecise Antibodies Cash From Financing History

DateAnnualQuarterlyTTM
Oct 2024
-
$1.52 M(-22.7%)
$4.77 M(+57.6%)
Jul 2024
-
$1.97 M(+136.7%)
$3.03 M(+300.5%)
Apr 2024
$756.00 K(-261.9%)
$831.60 K(+84.5%)
$756.00 K(-307.4%)
Jan 2024
-
$450.80 K(-302.1%)
-$364.60 K(-64.4%)
Oct 2023
-
-$223.10 K(-26.4%)
-$1.02 M(+57.1%)
Jul 2023
-
-$303.30 K(+4.9%)
-$652.20 K(+39.7%)
Apr 2023
-$467.00 K(-120.3%)
-$289.00 K(+37.9%)
-$466.90 K(-120.7%)
Jan 2023
-
-$209.50 K(-240.0%)
$2.26 M(-7.0%)
Oct 2022
-
$149.60 K(-226.8%)
$2.43 M(+3.4%)
Jul 2022
-
-$118.00 K(-104.8%)
$2.35 M(+2.3%)
Apr 2022
$2.30 M(-93.1%)
$2.44 M(-6274.4%)
$2.30 M(-89.4%)
Jan 2022
-
-$39.50 K(-157.2%)
$21.64 M(-1.9%)
Oct 2021
-
$69.10 K(-140.4%)
$22.05 M(-27.4%)
Jul 2021
-
-$170.90 K(-100.8%)
$30.37 M(-8.4%)
Apr 2021
$33.15 M(>+9900.0%)
$21.78 M(+5694.3%)
$33.15 M(+180.8%)
Jan 2021
-
$375.90 K(-95.5%)
$11.81 M(+3.6%)
Oct 2020
-
$8.38 M(+221.2%)
$11.40 M(+303.8%)
Jul 2020
-
$2.61 M(+496.3%)
$2.82 M(+2064.3%)
Apr 2020
$130.30 K(-98.2%)
$437.70 K(-1354.2%)
$130.40 K(-148.5%)
Jan 2020
-
-$34.90 K(-81.7%)
-$268.80 K(-36.3%)
Oct 2019
-
-$190.40 K(+132.2%)
-$422.30 K(-106.7%)
Jul 2019
-
-$82.00 K(-313.0%)
$6.35 M(-10.6%)
Apr 2019
$7.10 M(-7.6%)
$38.50 K(-120.4%)
$7.10 M(-32.4%)
Jan 2019
-
-$188.40 K(-102.9%)
$10.49 M(-2.4%)
Oct 2018
-
$6.58 M(+884.7%)
$10.75 M(+29.7%)
Jul 2018
-
$668.10 K(-80.6%)
$8.29 M(+8.0%)
Apr 2018
$7.68 M(+219.5%)
$3.44 M(+4705.6%)
$7.68 M(+80.9%)
Jan 2018
-
$71.50 K(-98.3%)
$4.25 M(+1.7%)
Oct 2017
-
$4.12 M(+7214.4%)
$4.17 M(+821.5%)
Jul 2017
-
$56.30 K(-85.8%)
$453.00 K(+14.0%)
Apr 2017
$2.40 M(>+9900.0%)
-
-
Sep 2016
-
$396.70 K(>+9900.0%)
$397.30 K(>+9900.0%)
Dec 2015
$600.00(-220.0%)
-
-
Dec 2015
-
$600.00(>+9900.0%)
$600.00(>+9900.0%)
Sep 2015
-
$0.00(-100.0%)
$0.00(-100.0%)
Dec 2014
-$500.00(-100.3%)
-
-
Dec 2013
$143.60 K(>+9900.0%)
-
-
Dec 2013
-
$143.60 K(-480.9%)
$143.60 K(>+9900.0%)
Jun 2013
-
-$37.70 K(-200.0%)
$0.00(-100.0%)
Mar 2013
-
$37.70 K(>+9900.0%)
$37.70 K(>+9900.0%)
Dec 2012
$0.00(-100.0%)
-
-
Dec 2012
-
$0.00(0.0%)
$0.00(-100.0%)
Mar 2012
-
$0.00(-100.0%)
$50.60 K(0.0%)
Dec 2011
$50.60 K(>+9900.0%)
-
-
Dec 2011
-
$50.60 K(>+9900.0%)
$50.60 K(>+9900.0%)
Sep 2011
-
$0.00(0.0%)
$0.00(0.0%)
Dec 2010
$0.00(-100.0%)
-
-
Dec 2010
-
$0.00(0.0%)
$0.00(0.0%)
Sep 2010
-
$0.00(-100.0%)
$0.00(-100.0%)
Dec 2008
$1.77 M(+375.2%)
-
-
Dec 2008
-
-$38.40 K(-102.1%)
$1.77 M(-1.7%)
Sep 2008
-
$1.80 M(<-9900.0%)
$1.80 M(>+9900.0%)
Jun 2008
-
-$800.00(-124.2%)
$12.10 K(-96.8%)
Mar 2008
-
$3300.00(-138.8%)
$377.20 K(+1.5%)
Dec 2007
$371.80 K
-
-
DateAnnualQuarterlyTTM
Dec 2007
-
-$8500.00(-147.0%)
$371.80 K(+183.8%)
Sep 2007
-
$18.10 K(-95.0%)
$131.00 K(+15.2%)
Jun 2007
-
$364.30 K(<-9900.0%)
$113.70 K(-92.8%)
Mar 2007
-
-$2100.00(-99.2%)
$1.58 M(-2.1%)
Dec 2006
$1.61 M(+2505.0%)
-
-
Dec 2006
-
-$249.30 K(<-9900.0%)
$1.61 M(-12.9%)
Sep 2006
-
$800.00(-100.0%)
$1.85 M(-3.2%)
Jun 2006
-
$1.83 M(+5803.2%)
$1.91 M(+5937.5%)
Mar 2006
-
$31.00 K(-416.3%)
$31.70 K(-48.8%)
Dec 2005
$61.90 K(-97.2%)
-
-
Dec 2005
-
-$9800.00(-115.6%)
$61.90 K(-96.2%)
Sep 2005
-
$62.70 K(-220.1%)
$1.61 M(-2.0%)
Jun 2005
-
-$52.20 K(-185.3%)
$1.64 M(-1.9%)
Mar 2005
-
$61.20 K(-96.0%)
$1.68 M(-25.3%)
Dec 2004
$2.25 M(+232.3%)
-
-
Dec 2004
-
$1.54 M(+1498.2%)
$2.25 M(+157.8%)
Sep 2004
-
$96.30 K(-593.8%)
$871.30 K(-28.2%)
Jun 2004
-
-$19.50 K(-103.1%)
$1.21 M(-2.9%)
Mar 2004
-
$630.50 K(+284.5%)
$1.25 M(+84.9%)
Dec 2003
$676.10 K(+251.4%)
-
-
Dec 2003
-
$164.00 K(-62.6%)
$676.10 K(+32.3%)
Sep 2003
-
$438.80 K(+2481.2%)
$511.20 K(+663.0%)
Jun 2003
-
$17.00 K(-69.8%)
$67.00 K(-64.3%)
Mar 2003
-
$56.30 K(-6355.6%)
$187.80 K(-2.4%)
Dec 2002
$192.40 K(+203.9%)
-
-
Dec 2002
-
-$900.00(-83.3%)
$192.50 K(+5.7%)
Sep 2002
-
-$5400.00(-103.9%)
$182.20 K(-174.4%)
Jun 2002
-
$137.80 K(+125.9%)
-$245.00 K(-297.3%)
Mar 2002
-
$61.00 K(-644.6%)
$124.20 K(+96.5%)
Dec 2001
$63.30 K(-87.0%)
-
-
Dec 2001
-
-$11.20 K(-97.4%)
$63.20 K(-87.6%)
Sep 2001
-
-$432.60 K(-185.3%)
$508.50 K(-47.4%)
Jun 2001
-
$507.00 K(>+9900.0%)
$966.30 K(+98.0%)
Mar 2001
-
$0.00(-100.0%)
$488.10 K(0.0%)
Dec 2000
$488.10 K(+2581.9%)
-
-
Dec 2000
-
$434.10 K(+1622.6%)
$488.10 K(+745.9%)
Sep 2000
-
$25.20 K(-12.5%)
$57.70 K(+78.1%)
Jun 2000
-
$28.80 K(>+9900.0%)
$32.40 K(+290.4%)
Mar 2000
-
$0.00(-100.0%)
$8300.00(-54.4%)
Dec 1999
$18.20 K(+1720.0%)
-
-
Dec 1999
-
$3700.00(-3800.0%)
$18.20 K(+17.4%)
Sep 1999
-
-$100.00(-102.1%)
$15.50 K(-0.6%)
Jun 1999
-
$4700.00(-52.5%)
$15.60 K(+43.1%)
Mar 1999
-
$9900.00(+890.0%)
$10.90 K(+990.0%)
Dec 1998
$1000.00(+233.3%)
-
-
Dec 1998
-
$1000.00(>+9900.0%)
$1000.00(+233.3%)
Sep 1998
-
$0.00(0.0%)
$300.00(0.0%)
Jun 1998
-
$0.00(0.0%)
$300.00(0.0%)
Mar 1998
-
$0.00(-100.0%)
$300.00(0.0%)
Dec 1997
$300.00(-100.0%)
-
-
Dec 1997
-
$300.00(>+9900.0%)
$300.00(>+9900.0%)
Sep 1997
-
$0.00(0.0%)
$0.00(0.0%)
Jun 1997
-
$0.00(0.0%)
$0.00(0.0%)
Mar 1997
-
$0.00
$0.00
Dec 1996
$928.80 K
-
-

FAQ

  • What is ImmunoPrecise Antibodies annual cash flow from financing activities?
  • What is the all time high annual CFF for ImmunoPrecise Antibodies?
  • What is ImmunoPrecise Antibodies annual CFF year-on-year change?
  • What is ImmunoPrecise Antibodies quarterly cash flow from financing activities?
  • What is the all time high quarterly CFF for ImmunoPrecise Antibodies?
  • What is ImmunoPrecise Antibodies quarterly CFF year-on-year change?
  • What is ImmunoPrecise Antibodies TTM cash flow from financing activities?
  • What is the all time high TTM CFF for ImmunoPrecise Antibodies?
  • What is ImmunoPrecise Antibodies TTM CFF year-on-year change?

What is ImmunoPrecise Antibodies annual cash flow from financing activities?

The current annual CFF of IPA is $756.00 K

What is the all time high annual CFF for ImmunoPrecise Antibodies?

ImmunoPrecise Antibodies all-time high annual cash flow from financing activities is $33.15 M

What is ImmunoPrecise Antibodies annual CFF year-on-year change?

Over the past year, IPA annual cash flow from financing activities has changed by +$1.22 M (+261.88%)

What is ImmunoPrecise Antibodies quarterly cash flow from financing activities?

The current quarterly CFF of IPA is $1.52 M

What is the all time high quarterly CFF for ImmunoPrecise Antibodies?

ImmunoPrecise Antibodies all-time high quarterly cash flow from financing activities is $21.78 M

What is ImmunoPrecise Antibodies quarterly CFF year-on-year change?

Over the past year, IPA quarterly cash flow from financing activities has changed by -$446.80 K (-22.70%)

What is ImmunoPrecise Antibodies TTM cash flow from financing activities?

The current TTM CFF of IPA is $4.77 M

What is the all time high TTM CFF for ImmunoPrecise Antibodies?

ImmunoPrecise Antibodies all-time high TTM cash flow from financing activities is $33.15 M

What is ImmunoPrecise Antibodies TTM CFF year-on-year change?

Over the past year, IPA TTM cash flow from financing activities has changed by +$1.74 M (+57.62%)